<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614063</url>
  </required_header>
  <id_info>
    <org_study_id>XPF-010-301</org_study_id>
    <nct_id>NCT05614063</nct_id>
  </id_info>
  <brief_title>A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures</brief_title>
  <acronym>X-TOLE2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xenon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study&#xD;
      that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as&#xD;
      adjunctive therapy in focal-onset seizures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 360 subjects will be randomized in a blinded manner to one of two active&#xD;
      treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo). Eligible&#xD;
      subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by&#xD;
      12 weeks of blinded treatment. In order to be included in the study, subjects must be treated&#xD;
      with a stable dose of 1 to 3 allowable antiseizure medications (ASMs) for at least one month&#xD;
      prior to screening, during baseline, and throughout the double-blind treatment period (DBP)&#xD;
      of the study. During the DBP, subjects will be instructed to orally take XEN1101 or placebo&#xD;
      once daily with an evening meal.&#xD;
&#xD;
      Subjects who complete the 12-week DBP will have the opportunity to qualify and enroll in a&#xD;
      separate open-label extension (OLE) study for continued treatment with XEN1101. Subjects who&#xD;
      do not enroll in the OLE will enter a 8-week post treatment follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo.</measure>
    <time_frame>From baseline through to the double blind period (week 12)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo.</measure>
    <time_frame>From baseline through to the double blind period (week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPC in weekly (7 days) focal seizure frequency from baseline to Week 1 for XEN1101 versus placebo.</measure>
    <time_frame>From baseline through to the week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing &quot;at least much improved&quot; (including &quot;much&quot; and &quot;very much improved&quot;) in Patient Global Impression of Change (PGI-C).</measure>
    <time_frame>From baseline through to the double blind period (week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess adverse events as criteria for safety and tolerability of XEN1101</measure>
    <time_frame>From screening through to 56 days post-final dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Focal Onset Seizures</condition>
  <arm_group>
    <arm_group_label>XEN1101 25 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XEN1101 25 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XEN1101 15 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XEN1101 15 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XEN1101</intervention_name>
    <description>XEN1101 Capsules</description>
    <arm_group_label>XEN1101 15 mg/day</arm_group_label>
    <arm_group_label>XEN1101 25 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be properly informed of the nature and risks of the study and give informed consent in&#xD;
             writing, prior to entering the study&#xD;
&#xD;
          -  Diagnosis (≥2 years) of focal epilepsy according to the International League Against&#xD;
             Epilepsy (ILAE) Classification of Epilepsy (2017). Subject must have had adequate&#xD;
             trials of at least 2 ASMs, which were given (and tolerated) at adequate therapeutic&#xD;
             doses, without achieving sustained seizure freedom.&#xD;
&#xD;
          -  Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month&#xD;
             prior to screening, during baseline, and throughout the duration of the DBP&#xD;
&#xD;
          -  Able to keep accurate seizure diaries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously documented electroencephalogram which shows any pattern not consistent with&#xD;
             focal etiology of seizures.&#xD;
&#xD;
          -  History of focal aware non-motor seizures only, non-epileptic psychogenic seizure,&#xD;
             primary generalized seizure, developmental and epileptic encephalopathy, including&#xD;
             Lennox-Gastaut syndrome.&#xD;
&#xD;
          -  Seizures secondary to drug or alcohol use, ongoing infection, neoplasia, demyelinating&#xD;
             disease, degenerative neurological disease, metabolic illness, progressive structural&#xD;
             lesion, encephalopathy, or progressive central nervous system (CNS) disease.&#xD;
&#xD;
          -  History of status epilepticus or repetitive seizures within the 12-month period&#xD;
             preceding Visit 1 where the individual seizures cannot be counted.&#xD;
&#xD;
          -  History of neurosurgery for seizures &lt;1 year prior to Visit 1, or radiosurgery &lt;2&#xD;
             years prior to enrollment.&#xD;
&#xD;
          -  Any medical condition or personal circumstance that, in the opinion of the&#xD;
             investigator, exposes the subject to unacceptable risk by participating in the study&#xD;
             or prevents adherence to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Xenon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xenon Medical Affairs</last_name>
    <phone>1-604-484-3300</phone>
    <email>XenonCares@xenon-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trials, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute of Orlando, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panhandle Research &amp; Medical Clinic</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Epilepsy and Sleep Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northeast Epilepsy Group</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Epilepsy Care Center (AECC)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 6, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

